北京昭衍生物技术有限公司

What 北京昭衍生物技术有限公司 does

Beijing JOINN Biologics (北京昭衍生物技术有限公司) is a large-molecule contract development and manufacturing organization (CDMO) spun off in 2018 from Beijing JOINN New Drug Research Center (昭衍新药, 603127.SH/6127.HK) and operating as a non-listed subsidiary. The company serves global innovative drug developers across the full biologics lifecycle, offering one-stop services from cell line construction, process development, analytical method development, pilot-scale production, to commercial-scale GMP manufacturing. Its service portfolio spans four technology platforms: mammalian cell CDMO (CHO-based antibody, bispecific, fusion protein, and enzyme production), microbial fermentation CDMO (recombinant protein, plasmid, gene therapy, recombinant vaccines), gene therapy CDMO (adenovirus, AAV, lentivirus vectors), and antibody-drug conjugate (ADC) CDMO (from discovery to IND filing). The company is dual-headquartered in Beijing and Guangzhou, with US operations in the San Francisco Bay Area and Sacramento, and a new manufacturing site in Xuchang (Henan); it has cumulatively served over 200 projects and supported more than 50 IND approvals globally.

The company's core technical differentiator is its fully proprietary host cell line platform, including CHO-K1, CHO-K1-TGZ (FUT8 knockout, which enhances ADCC efficacy of expressed antibodies by approximately 43x), and CHO-K1-GSGZ (GS knockout) strains, with average yields exceeding 6 g/L. Cell line products are licensed globally to customers, shifting downstream IP royalty risk away from clients. Manufacturing infrastructure includes 17×2000L single-use bioreactor lines in China (34,000L total), a Guangdong KUBio modular facility, and a Beijing base designed for 100,000L capacity post-completion. Regulatory positioning is broad: FDA Drug Manufacturing License for the US site (2020), EU QP audit pass (2021), USDA dual certification (2023, world's first commercial cultivated meat facility), CNAS laboratory accreditation (2024), and MIIT first-batch biomanufacturing pilot platform selection (2025, the only Beijing entry).

Revenue is generated primarily through project-based professional services (CDMO contracts) plus cell line licensing and analytical testing services. Notable customers include 舒泰神 (STSA-1002 anti-C5a mAb, 2020 FDA IND), 依生生物 (recombinant COVID vaccine, UAE Phase I), 步长制药 (7-year strategic agreement), 吉诺卫 (recombinant HSV vaccine, 2024 China/US IND), 福贝生物 (FB1003 chronic pain mAb, 2024 Australia Phase I), 舜景生物 (SGC001 acute AMI mAb, 2024 FDA IND), 热景生物 (2026 strategic cooperation), and 博沃生物 (vaccine pipeline). The company has raised approximately $260M in equity across a $60M Series A (2019, Huagai Capital lead), $150M Series B (2021, CPE Yuanfeng lead), and $50M Series B+ (2021), and ranks among the 2025 China Large-Molecule CDMO TOP20. Strategic moves in 2025 included the asset acquisition of Lonza's Guangzhou CDMO facility and the September 2025 grand opening of Guangzhou JOINN Biologics, signaling a transition from a Beijing-centric operation to a multi-site, multi-platform national CDMO platform.

Name

北京昭衍生物技术有限公司

Legal name

北京昭衍生物技术有限公司

Website

https://joinnbio.com.cn

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Beijing JOINN Biologics is a large-molecule CDMO spun off from JOINN New Drug, providing one-stop biologics development and GMP manufacturing services across mammalian cells, microbial fermentation, gene therapy, and ADC platforms for global innovative drug developers.

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing (CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGABAC

Biologics (mAbs/Recombinant Proteins) CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

SECONDARYHLAGABAG

Drug Substance–Drug Product Integrated CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

SECONDARYHLAGABAE

Gene Therapy (Viral Vector/Plasmid) CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

SECONDARYHLAGABAH

Sterile Fill-Finish & Aseptic Manufacturing CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

SECONDARYHLAGABAK

Clinical Trial Material (CTM) Manufacturing & Supply CDMO

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

SECONDARYHLAAAKAA

Biologic API/Drug Substance Manufacturing Services

Healthcare & Life Sciences/Biotechnology & Biologics/Biomanufacturing Services

Keywords

• Biologics CDMO services
• Antibody drug development
• Gene therapy manufacturing
• ADC contract manufacturing
• Biopharmaceutical production

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. CDMO服务收入: 作为制药CDMO企业，昭衍生物通过提供从细胞株构建、工艺开发、中试生产到商业化生产的一站式服务获取收入。服务涵盖哺乳动物细胞、微生物发酵、基因治疗、抗体偶联药物(ADC)等多个领域，按项目制收费。
2. 分析检测服务: 提供完整的分析方法学服务，支持重组蛋白药物、抗体药物、生物制剂、疫苗的筛选、开发、分析与表征研究，按服务项目收费。
3. 细胞产品销售: 销售具有自主知识产权的CHO-K1、CHO-K1-TGZ(FUT8-)、CHO-K1-GSGZ（GS-）宿主细胞，可根据客户需求提供全球商业化授权方案。

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

JOINN Biologics is a one-stop biologics Contract Development and Manufacturing Organization (CDMO) that delivers cell line construction, process development, scale-up, GMP manufacturing, analytical testing, formulation, and regulatory filing services for recombinant proteins, monoclonal antibodies, bispecific antibodies, gene therapy products, and antibody-drug conjugates (ADCs) across mammalian cell, microbial fermentation, gene therapy, and ADC platforms. Its services span preclinical through commercial production and are designed for global biopharmaceutical R&D institutions, biotech startups, and large pharmaceutical companies seeking China–U.S. dual supply.

Differentiator

Problem solved

Functional benefit

Products and services

• Mammalian Cell CDMO Services

Quantifiable outcome

• 累计服务项目数超过200个，获得IND批件超过50个
• +4 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Five partnerships are on record, tiered core and major.

• 北京热景生物技术股份有限公司coreStrategic or Co-development Partner · 26 February 20262026年2月26日，昭衍生物与热景生物达成战略合作，建立长期稳定的战略合作伙伴关系。昭衍生物将为热景生物的新药研发速度和研发质量提供保障。热景生物聚焦生物医药领域，于2019年9月在上海证券交易所科创板上市（股票代码：688068），布局核酸药物、抗体药物及大健康等前沿领域。
• 四川泸州步长生物制药有限公司coreStrategic or Co-development Partner · 1 August 20222022年8月，昭衍生物与步长生物达成战略合作。未来7年，昭衍生物将为步长生物产品的研发和生产提供服务，全面赋能其产品管线的推进。步长生物是山东步长制药股份有限公司的全资子公司，专注于抗体、融合蛋白等生物药优势领域的探索与布局。
• 河南新天地药业股份有限公司majorStrategic or Co-development Partner · 9 June 2022昭衍生物与新天地药业共同打造符合GMP标准的小分子原料药CDMO一站式服务平台，提供原料药工艺开发服务，为注册起始原料、中间体及API制定控制策略，以及为客户提供完整的工艺验证服务。平台涵盖公斤级实验室、多功能中试生产车间和商业化生产车间。
• 北京康明百奥新药研发有限公司majorTechnology or Integration昭衍生物与康明百奥签署战略合作协议，共同推出Mab-Edit糖工程抗体药物CDMO服务技术平台。平台以Mab-Edit抗体编辑稳定高表达细胞株为基础，为客户实现创新抗体药物一站式技术服务，应用先进的抗体编辑方法提高抗体药物的ADCC活性。
• 上海博沃生物科技有限公司majorStrategic or Co-development Partner昭衍利用其在临床试验领域的丰富经验，为博沃生物疫苗产品的研发、评价、课题申报等提供强有力的支持。博沃生物将通过昭衍一站式生物药物研发、生产、临床研究平台，实现疫苗产品从研发、生产、临床前到临床的无缝衔接。

Scale indicators13 records

Recent moves17 records

Expansion highlights7 records

Broad incumbents

• Samsung Biologics: South Korea-based global large-molecule CDMO with multi-hundred-thousand-liter installed capacity and a full-service portfolio from cell line to commercial aseptic fill-finish. Competes with JOINN Biologics for tier-1 innovator accounts and represents the scale benchmark for late-phase programs.
• Lonza: Global leader in biologics CDMO with a comprehensive mammalian and microbial manufacturing network. Directly relevant as the seller of the Guangzhou facility that JOINN Biologics acquired in 2025; competes at the global commercial-manufacturing tier where JOINN is now positioning.
• AGC Biologics: Global CDMO offering mammalian and microbial biologics manufacturing plus cell and gene therapy services. Comparable to JOINN Biologics in modality breadth but with deeper commercial-scale capacity and longer regulatory track record.
• Catalent (Novo Holdings): Global CDMO with biologics, cell therapy, and oral/injectable sterile manufacturing capabilities. Recently acquired by Novo Holdings. Overlaps with JOINN Biologics in biological drug substance, fill-finish, and ADC development services.
• Boehringer Ingelheim BioXcellence: Global biologics CDMO division of Boehringer Ingelheim, offering mammalian cell culture, microbial, and cell therapy services. Competes with JOINN Biologics for innovator pipeline outsourcing, particularly in the European and US markets.

Direct peers

• Pharmaron: Chinese-headquartered CDMO offering biologics (mAb, ADC) and small molecule services to global pharma. Competes with JOINN Biologics in biologics CDMO with a broader CRO/CDMO portfolio, and benefits from a comparable international footprint (China, US, UK).
• Asymchem: Chinese CDMO with strength in small-molecule API and growing biologics offering. Comparable to JOINN Biologics in being a Chinese-headquartered CDMO serving global pharma, though Asymchem's biologics platform is smaller and more recent.
• WuXi Biologics: The largest Chinese biologics CDMO, offering end-to-end discovery, development, and manufacturing services for mAbs, bispecifics, ADCs, and recombinant proteins. Directly competes with JOINN Biologics across the same target customer base of global innovative drug developers, with substantially larger installed capacity.
• GenScript ProBio: The CDMO subsidiary of GenScript Biotech, providing cell line construction, process development, and GMP manufacturing for antibodies, recombinant proteins, plasmids, and viral vectors. Closely comparable to JOINN Biologics in scale, modality mix, and biopharma customer orientation.

Others

• JOINN New Drug (JOINN Biologics' parent): Listed Chinese preclinical CRO (603127.SH/6127.HK) and parent company of JOINN Biologics. Provides safety evaluation, pharmacology, and related CRO services; serves as the originator of the CDMO subsidiary and exercises governance control over it.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights8 records

Customer concentration

• LinkedInlinkedin.com/company/%E5%8C%97%E4%BA%AC%E6%98%AD%E8%A1%8D%E7%94%9F%E7%89%A9%E6%8A%80%E6%9C%AF%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 北京昭衍生物技术有限公司